Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Profound Medical ( (TSE:PRN) ) just unveiled an update.
Profound Medical reported its second quarter 2025 financial results, highlighting a 10% sequential growth in procedure volumes for its TULSA-PRO systems. The company is expanding its sales pipeline with 80 new systems in various stages of verification, negotiation, and contracting. The TULSA-PRO system has shown significant improvements in post-operative experiences compared to traditional methods, and the company is set to launch a new TULSA-AI Volume Reduction Module to enhance BPH treatment efficiency. Despite short-term delays in capital sales, the company remains optimistic about its growth prospects and plans to integrate its technology with Siemens Healthineers’ MR scanner by the end of 2025.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$12.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
Profound Medical’s stock score reflects the company’s strong revenue growth and strategic potential, balanced by operational inefficiencies and financial challenges. Technical indicators suggest caution due to bearish trends, while valuation remains a concern with negative earnings. Positive earnings call sentiment and future growth prospects are encouraging, yet immediate operational improvements are necessary for sustained success.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company that specializes in developing and marketing AI-powered, incision-free therapies for the ablation of diseased tissue. The company focuses on providing innovative solutions for prostate disease treatment, particularly through their TULSA-PRO system, which is designed to treat prostate cancer and benign prostatic hyperplasia (BPH).
Average Trading Volume: 6,061
Technical Sentiment Signal: Sell
Current Market Cap: C$232M
For a thorough assessment of PRN stock, go to TipRanks’ Stock Analysis page.